The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis.

ABSTRACT: Modest response rates to immunotherapy observed in advanced lung cancer patients underscore the need to identify reliable biomarkers and targets, enhancing both treatment decision-making and efficacy. Factors such as PD-L1 expression, tumor mutation burden, and a 'hot' tumor microenvironment with heightened effector T cell infiltration have consistently been associated with positive responses. In contrast, the predictive role of the abundantly present tumor-infiltrating myeloid cell (TIMs) fraction remains somewhat uncertain, partly explained by their towering variety in terms of ontogeny, phenotype, location, and function. Nevertheless, numerous preclinical and clinical studies established a clear link between lung cancer progression and alterations in intra- and extramedullary hematopoie

SUBMITTER: Calderon-Espinosa E 

PROVIDER: S-EPMC11324509 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature